Amgen Optimistic About 2020 Despite COVID-19 Impacts
Executive Summary
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.